StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
ANGOANGIODYNAMICS INC
stockpulse.co.kr
Nasdaq
$12.37▲ 0.00%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $511.1MShares out 41.3M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

32
  • 10.8Regular26.10.09 01:56
    10-QEarnings#●●●#●●●

    ANGIODYNAMICS INC

    AngioDynamics reported net sales of $80.915 million for the first quarter of fiscal year 2026, up from $75.711 million in the same period last year. The company recorded a net loss of $7.097 million, an improvement from the $10.903 million net loss reported in the prior year's quarter.…more

    $12.37+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.8Regular26.10.08 23:25
    DEFA14AOther

    ANGIODYNAMICS INC

    AngioDynamics, Inc. has filed additional definitive proxy materials (DEFA14A) regarding its upcoming shareholder meeting. This filing provides procedural information for voting and does not contain any updates regarding the company's financial status or capital structure.…more

    $12.37+0.00%vs prev close
    View filingShare
  • 10.8Pre-market26.10.08 21:16
    DEF 14AOther

    ANGIODYNAMICS INC

    AngioDynamics will hold its annual meeting of shareholders on November 17, 2026, to vote on director elections, auditor ratification, executive compensation, and an amendment to the 2020 Equity Incentive Plan. For the fiscal year ended May 31, 2026, the company reported a 9.5% increase in total revenue, driven by 18.4% growth in the Med Tech segment and 2.6% growth in the Med Device segment.…more

    $12.37+0.00%vs prev close
    View filingShare

31 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 3d agoPre-market26.10.21 21:43
    Bullish#●●●#●●●

    AngioDynamics Reports Positive Pancreatic Cancer Study Results and New CPT Code…more

    AngioDynamics announced that its IRE-based treatment strategy demonstrated improved overall survival in Stage III pancreatic cancer patients. Additionally, the company secured a new Category I CPT code for open pancreatic IRE ablation, effective January 1, 2027.…more

    $12.37+0.00%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 10.14Pre-market26.10.14 20:06

    ●●●●●●●● ●●●●● ●●●●●●

    Humana has updated its Medicare Advantage policy to cover the NanoKnife system for eligible prostate and liver cancer patients starting October 1. This coverage expansion is expected to improve patient access and potentially boost the company's revenue.…more

    $12.37+0.00%vs prev close
    ShareBenzinga
  • 10.8Regular26.10.09 02:44

    ●●●●●●●● ●●●●● ●●●●●●

    AngioDynamics shares fell over 21% despite reporting first-quarter financial results that exceeded analyst expectations and announcing a new CEO. While the company reaffirmed its fiscal 2027 guidance and received FDA approval for a new study, the stock faced significant selling pressure.…more

    $12.37+0.00%vs prev close
    ShareBenzinga

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →